Clinical Trial Update: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the pharmacokinetics and safety of TQ05105 tablets in renal-impairment subjects with myelofibrosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TQ05105

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Myelofibrosis | Phase 1 | Status: COMPLETED